BIOTISSUE HOLDINGS INC.
MIAMI, FLORIDA

BIOTISSUE HOLDINGS INC., headquartered in Miami, Florida, is a pioneer in the field of regenerative medicine. The company leverages its superior platform technology and cutting-edge scientific innovation to market amniotic and umbilical cord-based products globally. These products are used extensively by physicians in eye care, wound care, and orthopedics. TissueTech's proprietary technologies are clinically proven to enhance regenerative healing processes. With a rich legacy spanning over 30 years of developmental research funded partially by the National Institute of Health, BIOTISSUE HOLDINGS INC. was the first to commercialize human amniotic membrane and umbilical cord applications clinically. Incorporated in Florida as a DOMP on May 10, 2001, with the incorporation number P01000047112, it has established its main address at 7300 Corporate Center Drive, Ste. 700, Miami, FL, 33126, USA. Contact can be made via phone at (888) 295-8858 or (305) 412-4429, and more detailed information is available on their website at tissuetech.com. The company went through a name change from TISSUETECH, INC., with its last significant corporate event recorded on June 6, 2024, where it filed an amended and restated articles amendment. Its most recent annual report was submitted on April 8, 2024, covering the year 2024. The company is assigned a FEI Number of 65-1116071. Leadership includes directors such as Matt Rice, John Arnott, and Amy Tseng.